Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2008;102:959-965
Published online before print March 6, 2008, doi: 10.1161/CIRCRESAHA.107.164947
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
102/8/959    most recent
CIRCRESAHA.107.164947v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Métrich, M.
Right arrow Articles by Lezoualc’h, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Métrich, M.
Right arrow Articles by Lezoualc’h, F.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Substance via MeSH
Related Collections
Right arrow Cell signalling/signal transduction
Right arrow Heart failure - basic studies
Right arrow Hypertrophy
(Circulation Research. 2008;102:959.)
© 2008 American Heart Association, Inc.


Integrative Physiology

Epac Mediates β-Adrenergic Receptor–Induced Cardiomyocyte Hypertrophy

Mélanie Métrich, Alexandre Lucas, Monique Gastineau, Jane-Lise Samuel, Christophe Heymes, Eric Morel, Frank Lezoualc’h

From Inserm (M.M., A.L., M.G., E.M., F.L.), U769, Signalisation et Physiopathologie Cardiaque, Châtenay-Malabry; Univ Paris-Sud (M.M., A.L., M.G., E.M., F.L.), Faculté de Pharmacie, IFR141, UMR-S769, Châtenay-Malabry; Inserm (J.-L.S., C.H.), U689, Centre de Recherche Cardiovasculaire, Paris; and Université D. Diderot (J.-L.S., C.H.), Paris, France.

Correspondence to Frank Lezoualc’h, Inserm, U769, Faculté de Pharmacie, 5 rue JB Clément, Châtenay-Malabry, F-92296, France. E-mail: Frank.Lezoualch{at}u-psud.fr

Cardiac hypertrophy is promoted by adrenergic overactivation and can progress to heart failure, a leading cause of mortality worldwide. Although cAMP is among the most well-known signaling molecules produced by β-adrenergic receptor stimulation, its mechanism of action in cardiac hypertrophy is not fully understood. The identification of Epac (exchange protein directly activated by cAMP) proteins as novel sensors for cAMP has broken the dogma surrounding cAMP and protein kinase A. However, their role and regulation in the mature heart remain to be defined. Here, we show that cardiac hypertrophy induced by thoracic aortic constriction increases Epac1 expression in rat myocardium. Adult ventricular myocytes isolated from banded animals display an exaggerated cellular growth in response to Epac activation. At the molecular level, Epac1 hypertrophic effects are independent of its classic effector, Rap1, but rather involve the small GTPase Ras, the phosphatase calcineurin, and Ca2+/calmodulin-dependent protein kinase II. Importantly, we find that in response to β-adrenergic receptor stimulation, Epac1 activates Ras and induces adult cardiomyocyte hypertrophy in a cAMP-dependent but protein kinase A–independent manner. Knockdown of Epac1 strongly reduces β-adrenergic receptor–induced hypertrophic program. Finally, we report for the first time that Epac1 is mainly expressed in human heart as compared with Epac2 isoform and is increased in heart failure. Taken together, our data demonstrate that the guanine nucleotide exchange factor Epac1 contributes to the hypertrophic effect of β-adrenergic receptor in a protein kinase A–independent fashion and may, therefore, represent a novel therapeutic target for the treatment of cardiac disorders.


Key Words: G protein–coupled receptor • small G protein • cardiac hypertrophy




This article has been cited by other articles:


Home page
Circ. Res.Home page
A. Abi-Gerges, W. Richter, F. Lefebvre, P. Mateo, A. Varin, C. Heymes, J.-L. Samuel, C. Lugnier, M. Conti, R. Fischmeister, et al.
Decreased Expression and Activity of cAMP Phosphodiesterases in Cardiac Hypertrophy and Its Impact on {beta}-Adrenergic cAMP Signals
Circ. Res., October 9, 2009; 105(8): 784 - 792.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
F. Lezoualc'h
Epac in melanoma: a contributor to tumor cell physiology? Focus on "Epac increases melanoma cell migration by a heparin sulfate-related mechanism"
Am J Physiol Cell Physiol, October 1, 2009; 297(4): C797 - C799.
[Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
O. Cazorla, A. Lucas, F. Poirier, A. Lacampagne, and F. Lezoualc'h
The cAMP binding protein Epac regulates cardiac myofilament function
PNAS, August 18, 2009; 106(33): 14144 - 14149.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
X. Ye, J. L. Shobe, S. K. Sharma, A. Marina, and T. J. Carew
Small G proteins exhibit pattern sensitivity in MAPK activation during the induction of memory and synaptic facilitation in Aplysia
PNAS, December 23, 2008; 105(51): 20511 - 20516.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Huang, J. M. Shelton, J. A. Richardson, K. E. Kamm, and J. T. Stull
Myosin Regulatory Light Chain Phosphorylation Attenuates Cardiac Hypertrophy
J. Biol. Chem., July 11, 2008; 283(28): 19748 - 19756.
[Abstract] [Full Text] [PDF]